{"id":"ddavp-inhalant-product","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasal congestion or irritation"},{"rate":null,"effect":"Hyponatremia (water intoxication)"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal cramping"}]},"_chembl":{"chemblId":"CHEMBL2094006","moleculeType":"Small molecule","molecularWeight":"702.93"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DDAVP binds to V2 receptors on renal collecting duct cells, increasing aquaporin-2 water channel expression and promoting water reabsorption to concentrate urine and reduce polyuria. It also binds to V1 receptors on endothelial cells, stimulating release of von Willebrand factor and coagulation factor VIII, which improves hemostasis in bleeding disorders. The inhalant formulation provides rapid systemic absorption through the nasal mucosa.","oneSentence":"DDAVP (desmopressin) is a synthetic vasopressin analog that acts as an antidiuretic hormone (ADH) replacement, increasing water reabsorption in the kidneys and promoting von Willebrand factor and factor VIII release from endothelial cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:42.079Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Central diabetes insipidus"},{"name":"Nocturnal enuresis"},{"name":"Von Willebrand disease"},{"name":"Hemophilia A"}]},"trialDetails":[{"nctId":"NCT03379974","phase":"PHASE4","title":"Exercise Versus DDAVP in Patients With Mild Hemophilia A","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2018-07-31","conditions":"Hemophilia A","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IN DDAVP"],"phase":"marketed","status":"active","brandName":"DDAVP Inhalant Product","genericName":"DDAVP Inhalant Product","companyName":"Nationwide Children's Hospital","companyId":"nationwide-children-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DDAVP (desmopressin) is a synthetic vasopressin analog that acts as an antidiuretic hormone (ADH) replacement, increasing water reabsorption in the kidneys and promoting von Willebrand factor and factor VIII release from endothelial cells. Used for Central diabetes insipidus, Nocturnal enuresis, Von Willebrand disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}